You are here


SBIR Tech Transfer

Goal: To help move commercially-viable technologies from the NIH Intramural Program to the marketplace.
Program AnnouncementPA-18-705 – SBIR Technology Transfer

Current Expiration Date: September 6, 2021 per issuance of NOT-NS-21-042. (Subject to re-issuance in 2021)

Combining technology transfer partnering mechanisms with SBIR funding to move inventions from bench research to market
  • NCI strongly recommends companies contact TTC and/or NCI SBIR representatives prior to starting the grant application. 
  • Companies that have identified an NCI technology to develop are recommended to discuss a proposed research plan with the NCI researcher
    • NCI TTC will facilitate confidential discussions with the NCI researcher prior to developing a research plan. 
  • An SBIR-TT Phase I awardee will be granted a royalty-free, non-exclusive research-use license to use NIH-owned and patented background inventions within the scope and term of the award.
  • Upon notification that Phase I grant will be awarded, the company needs to apply for a research use license as soon as possible so that it can be granted when the award is made.
  • Upon receiving an SBIR-TT Phase I grant, the awardee should apply to the NCI TTC for a commercialization license to make, use, and sell products or services incorporating the NIH background invention. A commercialization license is required in order to accept an SBIR-TT Phase II grant. This can be a regular commercialization or a Start-Up License.
  • The SBIR-TT grantee works closely with the NCI PI as defined in the SBIR application. 

As part of the SBIR-TT project, an NIH intramural investigator may provide assistance in a collaborative manner by providing resources  and/or discussions during the SBIR award period.

Please note:
  • No SBIR funds are allowed to go to the NIH intramural investigator or to the NIH intramural program.
  • R43/44 & R41/42 – Clinical Trial applications are not allowed.
  • Application Receipt Dates: Standard SBIR grant application dates
  • Budget: Changes each year. Fast-Track accepted.
    How Much Does It Cost?
    • Each party responsible for its own costs
    • CRADAs permit NCI to receive funds only to offset our costs for CRADA research
    • NCI cannot receive funding provided to the Collaborator from an NCI grant or contract – including SBIR
    • NCI cannot provide funding to the SBC under any of the TT agreements
    Collaborating with NCI intramural research via SBIR-TT Grants
    • NIH labs can co-develop under several different formats, depending on the need
    • Company can exchange IP with the NCI researcher (CDA invoked)
    • Company can utilize fixed asset resources at NCI and an FFRDC such as the Frederick National Laboratory for Cancer Research in Frederick, MD
    • Company cannot fund CRADA work in NCI lab using SBIR funds, however local, state, other federal, private, or investor funds can be used if accounted for.
    NCI SBIR-TT Points of Contact:

    Christie Canaria, Ph.D.
    Program Director
    NCI SBIR Program Office

    John D. Hewes, Ph.D.
    Senior Invention Development Specialist
    NCI Technology Transfer Center

    Thursday, April 15, 2021